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Background: We previously determined that newborn piglets orally gavaged with Ovalbumin (OVA) responded
to systemic OVA re-exposure with tolerance; if adjuvants were included in oral vaccine, piglets responded with
antibody-mediated immunity (Vet Immunol Immunopathol 161(3–4):211–21, 2014). Here, we will investigate
whether newborn piglets gavaged with a vaccine comprised of OVA plus unmethylated CpG oligodeoxynucleotides
(CpG; soluble component; OVA/CpG) combined with OVA plus CpG encapsulated within polyphosphazene
microparticles (MP; particulate component) responded with systemic and mucosal immunity. To monitor the
response to systemic antigen re-exposure, piglets were i.p.-immunized with OVA plus Incomplete Freund’s Adjuvant
(IFA) one month later.
Results: Newborn piglets (n = 5/group) were gavaged with a combined soluble and particulate vaccine consisting
of OVA (0.5-0.05 mg) plus 50 μg CpG and 0.5 mg OVA plus 50 μg CpG encapsulated within a polyphosphazene MP
(0.5 mg) referred to as OVA/CpG + MP. Control piglets were gavaged with saline alone. Piglets were i.p. immunized
with 10 mg OVA (or saline) in IFA at four weeks of age and then euthanized at eight weeks of age. We observed
significantly higher titres of serum anti-OVA immunoglobulin (Ig) IgM, IgA, IgG, IgG1, IgG2 and IgG in piglets
immunized with 0.05 mg OVA/CpG + MP relative to saline control animals. Thus, a single oral exposure at birth to a
combined soluble and particulate OVA vaccine including adjuvants can circumvent induction of oral tolerance which
impacts response to i.p. vaccination in later life. Further, piglets gavaged with 0.05 mg OVA/CpG + MP generated
significant anti-OVA IgG and IgG1 titres in lung compared to saline control piglets but results were comparable
to titres measured in parenteral control piglets. Peripheral blood mononuclear cells (PBMCs) ex vivo-stimulated
with OVA showed markedly decreased production of IL-10 cytokine after 72 hours relative to animal-matched
cells incubated with media alone. No production of IFN-γ was observed from any groups.
Conclusion: Newborn piglets gavaged with low dose soluble and particulate OVA plus CpG ODN and polyphosphazene
adjuvants produced antigen-specific antibodies in serum and lung after systemic re-exposure in later life. These
data indicate circumvention of oral tolerance but not induction of oral immunity.
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If exposure to an antigen by the oral route fails to
promote an oral immune response, any subsequent
re-exposure (even by a systemic route) results in suppres-
sion of immunity; this process is known as oral tolerance.
Oral tolerance is a major suppressive immunological
process designed to prevent local and peripheral over-
reaction to innocuous antigens [1,2]. Commensal bacteria
are critically required for proper gut-associated lymphoid
tissue (GALT) development and induction of oral tol-
erance [3,4]. Mucosal dendritic cells (DCs) play an
active role in inducing oral tolerance through mecha-
nisms which require retinoic acid, vitamin D, interleukin
(IL)-10, Transforming growth factor (TGF)-β, and
indoleamine-2,3,-dioxygenase [5-9]. In the mesenteric
lymph nodes (MLNs), T regulatory (Treg) cells undergo
differentiation and home back to the inductor site to in-
duce and/or maintain antigen-specific oral tolerance [8].
Several physical barriers prevent antigen/pathogen con-
tact with GALT and subsequent penetration of the gut
wall making targeted induction of oral immunity a sig-
nificant challenge [10,11]. The gut of the newborn piglet
is uniquely designed to be semi-permeable or ‘leaky’ for a
limited time to allow colostrum-derived cells, antibodies,
and other macromolecules such as albumin, cytokines,
antimicrobial peptides and many other bioactive prod-
ucts to be passively transferred to the piglets. These
maternally-derived cells and macromolecules traverse the
gut wall then enter into the vasculature where they play a
variety of roles including passive immunity against dis-
ease [12-15]. ‘Gut closure’ occurs within a few days after
birth in ruminants [16] and pigs [17], but it does not
occur until after weaning (two weeks of age) in rats
and mice [18-20]. In humans, a considerable amount of
‘gut-closure’ occurs both before birth and within a few
days after birth but it may in fact take up to two years to
reach the same level of impermeability that is observed
in the adult gut [21,22]. Once across the gut wall, anti-
gens may be able to interact with DCs within the sub-
epithelial dome which can then present antigens to T
cells within isolated lymphoid follicles and/or Peyer’s
Patches to promote induction of oral immunity rather
than being taken up by tolerogenic mucosal DCs
which promote oral tolerance [23,24]. Despite the
overwhelming propensity to respond to an oral antigen
with tolerance, oral vaccines are highly sought because
of their ease of administration. They are needle-free
and therefore present reduced risk of transmitting in-
fections and less need for qualified personnel to ad-
minister the vaccine. Moreover, an estimated 90% of
all pathogens invade through mucosal surfaces, there-
fore mucosal immunity (induced by mucosal vaccines)
offer the potential to control pathogens at their point
of entry.Previous work from our lab showed that rat pups and
lambs orally vaccinated starting the day after birth with
multiple doses of soluble ovalbumin (OVA; without
adjuvants) responded with immunity to subsequent in-
traperitoneal (i.p.) immunization [25,26]. In contrast, we
showed that newborn piglets orally immunized within
six hours after birth with single bolus of soluble OVA
then boosted through the i.p. route one month later
showed significantly lower anti-OVA immunoglobulin
(Ig) A titres and a strong trend towards lower anti-OVA
IgM, IgG1, IgG2 and IgG titres relative to the i.p. control
group indicating induction of oral tolerance [27]. These
data showed agreement with Haverson et al [28] who
demonstrated that newborn piglets orally vaccinated
once with OVA induced classical oral tolerance follow-
ing a systemic challenge by showing reduced specific
systemic IgG responses. When we included unmethy-
lated oligonucleotides containing CG oligodeoxynucleo-
tides (CpG ODNs) and soluble polyphosphazene in the
oral vaccine administered at birth, the response to i.p.
immunization one month later was induction of immun-
ity (i.e. increased serum anti-OVA IgA, IgM, IgG1, IgG2
and IgG titres relative to piglets immunized with OVA
alone) [27]. Clearly the components of the oral vaccine
administered at birth impacted the response to the
booster immunization one month later.
Factors contributing to induction of oral tolerance in-
clude: the host’s immunological maturity at time of ex-
posure, the timing and the frequency of exposure, and
the nature of the antigen [29-32]. We established that a
single bolus of soluble OVA with CpG ODN and poly-
phosphazene adjuvants administered the day after birth
induced oral immunity in piglets [27]. Our next step will
be to establish whether inclusion of the antigen in a par-
ticulate form promotes oral immunity and whether the
response could be observed at distal mucosal sites. To
test this hypothesis, conventionally reared neonatal pig-
lets were gavaged within six hours after birth with
0.5 mg or 0.05 mg OVA plus CpG ODN in a soluble
form as well as OVA plus CpG ODN encapsulated
within a polyphosphazene microparticle (MP) [33-35].
Systemic and mucosal antibody titres and ex vivo cyto-
kine production are assessed to determine antibody-
mediated and cell-mediated immunity.
Results
Explanation of vaccination procedure
Piglets were gavaged with a two-part vaccine consisting
of soluble OVA (0.5 mg or 0.05 mg) with 50 μg soluble
CpG 2395 (which together make up the soluble compo-
nents of the vaccine; OVA/CpG) as well as a MP encap-
sulating 0.5 mg OVA + 50 μg CpG 2395 (which
comprised the particulate part of the vaccine). These
vaccines will be referred to as 0.5 mg OVA/CpG +MP
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line is detailed in Figure 1. Piglets were gavaged at less
than six hours of age when their gut would be semi-
permeable with the idea that both the soluble OVA/CpG
and the OVA and CpG ODN within the MP would cross
the leaky gut wall. Polyphosphazene-based MPs are
water-soluble and would then dissolve over time to re-
lease the encapsulated OVA and CpG ODN thus acting
like a prime-boost [36,37]. Piglets were bled three days
after birth, day seven after birth, and weekly thereafter
(Figure 1, grey arrows specify bleed times). Piglets
were i.p. immunized with 10 mg OVA (or saline)
plus Incomplete Freund’s Adjuvant (IFA) at 28 days
of age and all piglets were euthanized at 49 days of age.
The i.p. control group received a saline gavage but piglets
were boosted with the i.p. vaccination (OVA + IFA) to act
as our primary i.p. vaccine control group.
Newborn piglets vaccinated by oral gavage responded
with significant serum anti-OVA IgM, IgA, and IgG1, IgG2
and IgG production after re-exposure by the i.p. route
The definition for oral tolerance is that oral exposure to
antigen which is subsequently encountered via a sys-
temic route triggers reduced immune responses (such as
antibody production) relative to animals exposed to anti-
gen systemically without prior oral exposure [38]. Previ-
ous work in our laboratory showed that animals orally
immunized six hours after birth with 5 mg or 0.05 mg
OVA responded to i.p. immunization at one month of
age with oral tolerance, not oral immunity [27]. There-
fore these groups (OVA alone without adjuvants) were
not repeated here. In the current trial, when we assessed
the serum antibody titres in the piglets prior to weaning
(less than day 21) for all groups, we observed negligibleFigure 1 Description and timeline of immunization protocol. Piglets (n = 5
unmethylated oligonucleotides containing CG oligodeoxynucleotides (CpG
2395 within a 0.5 mg PCEP polyphosphazene microparticles (MP). Gavage
group and the i.p. control group were gavaged with saline. With the exce
immunized at four weeks of age with 10 mg OVA in Incomplete Freunds
lung lavages were harvested. Blood was obtained on day three, day seve
for PBMC isolation.anti-OVA antibodies of any isotype indicating that the
sows did not pass any interfering OVA-specific passive
immunity to the piglets (data not shown). Even one
week after weaning (Figure 2, day 28), all isotypes of pig-
let serum anti-OVA antibodies titres were negligible sug-
gesting that oral gavage at birth with 0.5 mg or 0.05 mg
OVA/CpG +MP alone did not promote antibody-
mediated immunity. On day 42, which was two weeks
after the i.p. booster immunization, we observed a sig-
nificant increase in serum anti-OVA IgM (Figure 2A;
p < 0.05), IgA (Figure 2B; p < 0.05), IgG1 (Figure 2D;
p < 0.05), and IgG2 (Figure 2E; p < 0.05) titres in the
i.p. control group relative to the saline control group. The
group gavaged with 0.05 mg OVA/CpG +MP showed sig-
nificant induction of anti-OVA IgM (Figure 2A; p < 0.05),
IgA (Figure 2B; p < 0.01), IgG (Figure 2C; p < 0.05), IgG1
(Figure 2D; p < 0.01), and IgG2 (Figure 2E; p < 0.01) relative
to the saline control group suggesting that prior oral ex-
posure to low dose OVA circumvented induction of oral
tolerance. The animals gavaged with ten-fold higher dose
of soluble OVA (0.5 mg OVA/CpG +MP) showed a strong
trend towards increased anti-OVA antibody production
relative to the saline control group but the data were not
statistically significant.
On day 49, serum titres from animals within the i.p.
control group showed a significant increase in anti-OVA
IgG1 antibodies (Figure 2D; p < 0.05) relative to the sa-
line control group. In contrast, the group gavaged with
0.05 mg OVA/CpG +MP showed significantly more
anti-OVA IgM (Figure 2A; p < 0.05), IgA (Figure 2B;
p < 0.05), IgG1 (Figure 2D; p < 0.01), and IgG2 (Figure 2E;
p < 0.01) titres than what was observed in the saline con-
trol group. The group gavaged at birth with 0.5 mg
OVA/CpG +MP showed significantly more anti-OVA/group) were gavaged with ovalbumin (OVA) (0.05 mg or 0.5 mg) + 50 μg
2395) as a soluble vaccine as well as with 0.5 mg OVA + 50 μg CpG
s took place within six hours of birth. The negative control (saline)
ption of the saline control group, the remaining groups were i.p.
’ Adjuvant (IFA). At eight weeks of age, piglets were euthanized and
n and then weekly (grey arrows). At time of death, blood was drawn
Figure 2 (See legend on next page.)
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Figure 2 OVA-specific antibody-mediated immune responses in serum from newborn piglets gavaged with OVA then i.p. immunized
with OVA at four weeks of age. Piglets (n = 5/group) were gavaged and i.p. immunized as described in Figure 1. Control newborn piglets were
not gavaged or immunized with OVA. We measured serum anti-OVA IgM (A), IgA (B), IgG (C), IgG1 (D) and IgG2 (E) production on day 28, day
42 and day 49 after birth. Each data point represents an individual animal and median values are indicated by horizontal lines. *p < 0.05., **p < 0.01.
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antibodies compared to the saline control group, but the
other isotypes did not. Thus, unlike our previous data
which showed that piglets orally vaccinated with soluble
OVA alone induced oral tolerance [27], data from the
current trial shows that piglets orally vaccinated with
0.5 mg or 0.05 mg OVA/CpG +MP showed significant
induction of anti-OVA antibodies in serum indicating
circumvention of oral tolerance.
Newborn piglets vaccinated orally with low dose
OVA/CpG +MP responded with significant anti-OVA IgG1
and IgG titres in lung lavage after re-exposure by the
i.p. route
According to the ‘Common Mucosal Immune System’
theory, antigen-sensitized precursor B and T lympho-
cytes generated at one mucosal site (i.e. such as the gut)
can be detected at anatomically remote and functionally
distinct compartments (such as the respiratory mucosa)
[39-45]. After 49 days, the pigs were euthanized and
bronchoalveolar lavage was collected. Piglets gavaged
with saline but injected with OVA and IFA by the i.p.
route alone (i.e. the i.p. control group) failed to trigger
significant anti-OVA IgM (Figure 3A), IgA (Figure 3B),
IgG (Figure 3C), IgG1 (Figure 3D), or IgG (Figure 3E) ti-
tres relative to the saline control group. Newborn piglets
gavaged with 0.05 mg OVA/CpG +MP had very low
titres of anti-OVA IgM (Figure 3A), IgA (Figure 3B),
and IgG2 (Figure 3E) but the titres for anti-OVA IgG
(Figure 3C, p < 0.05) and IgG1 (Figure 3D; p < 0.05) were
statistically higher than the saline control group. Collect-
ively, these results suggest that oral exposure to OVA/
CpG +MP triggered low level mucosal immunity at a
distal site.
Neonatal piglets gavaged with OVA/CpG +MP did not
respond with induction of OVA-specific cell-mediated
immunity
Finally, we sought to determine whether neonatal piglets
orally gavaged with 0.5 mg or 0.05 mg OVA/CpG +MP
developed cell-mediated immunity as measured by
IFN-γ (Type 1 T-helper cell (Th1)) cytokines and IL-10
(Th2 cytokines). Peripheral blood mononuclear cells
(PBMCs) were collected at eight weeks of age and they
were restimulated ex vivo with OVA or media for 72 hours
before the supernatants were collected and antibody
titres were assessed. PBMCs did not show OVA-specificinduction of IFN-γ for any group except in the presence
of the mitogen Concanavalin A (data not shown). Inter-
estingly, we observed a decrease in production of the
anti-inflammatory cytokine IL-10 relative to unstimu-
lated (media control) cells in all groups including the
saline control groups. These data indicate that oral gav-
age of newborn piglets did not promote cell-mediated
immunity as measured at 8 weeks of age.
Discussion
Because the vast majority of infectious agents enter the
body through mucosal routes, it is reasonable to assume
that mucosal immunity which combats the infectious
agent prior to colonization and penetration would be
much more effective than systemic immunity. But it has
proven very challenging to design effective oral subunit
vaccine without the use of very strong mucosal adju-
vants such as cholera toxin [46,47]. The majority of clin-
ically approved oral vaccines for use in pigs are live
attenuated viruses or bacteria (www.vetvac.org/index.php).
One may speculate that in order to trigger an immune re-
sponse instead of tolerance, the pathogen must traverse
the gut wall and/or penetrate the epithelial cells lining the
gut wall. If this is the case, it is understandable that sub-
unit vaccines that lack strong adjuvants such as cholera
toxin should fail to promote immunity [48]. However,
such adjuvants cause significant side effects and are
therefore not in clinical use. Due to the inherent risk of at-
tenuated pathogen vaccines reverting to virulence, live
attenuated vaccines against pathogens such as Porcine
Reproductive and Respiratory Virus are not recommended
for use in seronegative herds and are therefore a reactive
vaccine instead of a proactive vaccine [49-51].
Previous work in our lab showed that oral adminis-
tration of soluble OVA in rat pups or lambs starting
immediately after birth was sufficient to promote oral
immunity or at minimum prevented induction of oral
tolerance [25,26]. In contrast, our research with piglets
showed that soluble OVA administered immediately after
birth triggered induction of oral tolerance [27]. However, if
CpG ODN and polyphosphazene adjuvants were included
in the soluble oral vaccine, there was instead evidence of
induction of serum antibody-mediated immunity in re-
sponse to systemic re-exposure in later life [27]. In the
current study, we investigated whether oral immunization
with a mixture of soluble and particulate OVA plus CpG
ODN and polyphosphazene adjuvants could promote oral
Figure 3 (See legend on next page.)
Pasternak et al. BMC Veterinary Research  (2015) 11:50 Page 6 of 11
(See figure on previous page.)
Figure 3 OVA-specific antibody-mediated immune responses in lung washes from newborn piglets gavaged with OVA then i.p.
immunized with OVA at four weeks of age. Piglets (n = 5/group) were gavaged and i.p. immunized as described in Figure 1. Control
newborn piglets were not gavaged or immunized with OVA. Lung lavages were collected four weeks post i.p. immunization and OVA-specific
serum IgM (A), IgA (B), IgG (C), IgG1 (D), and IgG2 (E) titres were measured. ELISA titres are expressed as the reciprocal of the highest dilution
resulting in a reading of two standard deviations above the negative control. Each data point represents an individual animal and median values
are indicated by horizontal lines. *p < 0.05, **p < 0.01.
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antibody-mediated immune responses were induced
in newborn piglets gavaged once on the day of birth
with 0.5 mg or 0.05 mg OVA/CpG +MP and subse-
quently boosted with OVA and IFA by the i.p. route one
month later. If oral tolerance to OVA had been induced
instead, re-exposure to the antigen by i.p. injection
should have resulted in a reduction of serum anti-OVA
antibody titres as observed in [27]. Anti-OVA IgG and
IgG1 titres in lung lavages were significantly induced in
piglets gavaged at birth with 0.05 mg OVA/CpG +MP in-
dicating induction of mucosal antibody-mediated im-
munity at a distal mucosal site. IgG has not traditionally
been recognized as a major mucosal immunoglobulin,
however there is growing evidence that oral vaccines can
elevate local and systemic IgG titres [52,53] and that IgG
antibodies may play a role in passive transfer of luminal
antigens across the gut wall using FcRN [54]. Therefore,
our data shows that vaccination of newborn piglets with
a joint soluble and particulate subunit vaccine triggered
systemic antibody-mediated immunity which contrasts
with what is reported in older piglets orally vaccinated
with soluble antigens or newborn piglets gavaged with
OVA alone [27,52].
Results from our lab showed that oral vaccination of
newborn lambs with OVA produced minimal cell-
mediated immunity as established by IFN-γ expression
and lymphocyte proliferation in ex vivo stimulated sple-
nocytes [26]. Similarly, ex vivo-stimulated mLN cells
from rat pups gavaged with OVA after birth failed to
produce significantly higher IFN-γ titres relative to cells
from pups gavaged after birth with saline [25]. In the
current study, we gavaged piglets with soluble and par-
ticulate OVA plus polyphosphazene and CpG ODN, the
latter of which is known to promote IFN-γ production
[55]. Despite inclusion of CpG ODN in the oral piglet
vaccine, IFN-γ production was negligible suggesting that
oral immunization of newborns may not induce signifi-
cant cell-mediated immunity.
Further studies must be undertaken to clarify the pre-
cise dose, vaccine formulation and timing of exposure
required for induction of cellular immunity as well as in-
cluding direct measurements of mucosal immunity. Ex-
periments are underway to elucidate the kinetics of gut
permeability and the impact this has on the mechanismsof antigen uptake and where antigen presentation to
lymphocytes occurs (i.e. in the Peyer’s patches, isolated
lymphoid follicles, or mesenteric lymph nodes). Should
early life oral vaccination consistently circumvent induc-
tion of oral tolerance and/or promote oral immunity, it
will have important implications for protecting against
infectious diseases in the very young and it may reduce
the number of carriers of disease-producing organisms
within a herd.
Conclusions
In the present study, we determined that low dose OVA/
CpG +MP circumvented induction of oral tolerance
with comparable serum anti-OVA antibodies relative to
the animals gavaged with 0.05 mg OVA/CpG +MP rela-
tive to the i.p. control animals. There was a trend to-
wards induction of mucosal immunity but the results
were not statistically significant. These results are intri-
guing and should be studied further to establish whether
it may be advisable to proactively orally vaccinate new-
born piglets to prevent induction of oral tolerance to
ensure that the they can respond appropriately to paren-
teral vaccines in later life.
Methods
Immunization procedure
This work was approved by the University of
Saskatchewan’s Animal Research Ethics Board, and
adhered to the Canadian Council on Animal Care guide-
lines for humane animal use. Pregnant Landrace-cross
sows were housed at VIDO with ad libitum access to
standard feed and water. Piglets were randomly assigned
to treatment groups. We gavaged piglets with a single
bolus of saline or 0.5 mg or 0.05 mg OVA (Sigma-Aldrich
Canada Ltd, Oakville, ON, Canada) plus 50 μg CpG 2395
(soluble components; 5′- TCGTCGTTTTCGGCGCGC
GCCG -3′ phosphorothioate oligodeoxy-nucleotide from
Merial Limited (Lyon, France)), as well as the particu-
late component comprised of 0.5 mg OVA+ 50 μg CpG
2395 + 500 μg poly [di(sodiumcarboxylatoethylphenoxy)-
phosphazene] (PCEP) (synthesized by Idaho National
Laboratory (Idaho Falls, ID, USA). (These doses were
extrapolated from a successful oral vaccination with
OVA in lambs and weight adjusted [26]). Microparticles
were formulated as detailed in [34]. A total volume of
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Tubing with a monojet catheter tip (Fisher Scientific Ltd.,
Ottawa, ON) gently inserted into the back of the throat.
Piglets were bleed on day three and day seven and then
weekly until day 49 (Grey arrows, Figure 1). All blood
samples were collected using Ethylenediaminetetraacetic
acid (EDTA) Vacutainers (BD Biosciences-Canada,
Mississauga, ON), centrifuged (4547 × g) and serum
stored at −20°C until antibody titres were measured. At
four weeks age, piglets were i.p.-injected with 10 mg
OVA plus IFA (Sigma-Aldrich). To generate the paren-
teral control group, piglets received saline by oral gavage
and they were i.p. immunization with OVA plus IFA at
four weeks as indicated above. This route was used be-
cause it is considered relevant for stimulating the muco-
sal tissues [56,57]. On day 49, piglets were euthanized
using 2 mL/10 lb body weight with Pentobarbital Sodium
Injection (240 mg/mL; Euthanyl, Bimeda-MTC Animal
Health Inc., Cambridge, ON). Lung lavages were ob-
tained at the end of the trial (Eight weeks; Figure 1). The
lung lavage was kept on ice until centrifuged at 400 × g at
4°C for 10 min, then cells were washed twice with
cold PBS, counted, and suspended to a final concen-
tration of 4 × 106 cells/mL in 10% complete Roswell
Park Memorial Institute (RPMI) medium (Gibco; Life
Technologies, Burlington, Ontario), supplemented with
0.2 mM L-glutamine, 0.1 mM HEPES, 0.05 mg/mL gen-
tamicin, 0.02 mM 2-mercaptoethanol (Sigma-Aldrich
for all), and 10% heat inactivated horse serum (Gibco;
Life Technologies). Cells were stored at -20°C until
used for cytokine ELISAs. Endotoxin concentration in
OVA was determined to be 8,000 U/ml using the Limulus
Amebocyte Lysate enzymatic assay QCL-1000 (Lonza
Group Ltd, Basel, Switzerland) according to the manufac-
turer’s instructions.
Serum and lung lavages ELISA
To measure OVA-specific antibody titres, blood sera
and lung lavages was obtained as indicated above and
ELISAs were performed as previously described [33].
Immunolon II microtiter plates (Dynex Technology Inc.,
Chantilly, VA, USA) were coated overnight at 4°C with
OVA at 500 μg/ml in carbonate coating buffer (15 mM
Na2CO3, 35 mM NaHCO3, pH 9.6; Sigma-Aldrich) and
100 μL of antigen added to each well. Wells were
washed six times with distilled H2O. Pig serum or lavage
samples were diluted as appropriate in Tris-buffered sa-
line plus 0.05% Tween (Sigma-Aldrich) then they were
added to the wells at 100 μL/well and incubated for two
hours at room temperature (RT). Wells were washed
again with distilled H2O and mouse anti-porcine IgA
(Ab Serotec, Raleigh, NC, #MCA 638, 1/300), mouse
anti-porcine IgG1 (Ab Serotec, #MCA 635, 1/600),
mouse anti-porcine IgG2 (Ab Serotec, #MCA 636, 1/300),or mouse anti-porcine IgM (Ab Serotec, #MCA 637,
1/100) were added to the wells in a 100 μL volume
and incubated for one hour at RT. Wells were washed
again with dH2O and goat anti-mouse IgG (H + L) al-
kaline phosphatase conjugated (KPL, Gaithersburg,
MD, USA, #075-1806, 1/5000) was added to each well
at 100 μL/well followed by incubation for one hour at
room temperature (RT). One hundred microlitres of
goat anti-porcine IgG alkaline phosphatase conjugated
(KPL, Gaithersburg, MD, USA, #15-14-06, 1/5000) to
each well was used for total IgG detection. Wells were
washed six times in dH2O before di(Tris) p-nitrophenyl
phosphate (PNPP; Sigma-Aldrich) was diluted 1 mg/mL
in PNPP substrate buffer (1 mM of MgCl2, 200 mM of
Tris-HCl, pH 9.8; Sigma-Aldrich) and 100 μL/well was
added to the wells. The reaction was allowed to develop
for 60 min before absorbance was read as optical
density (OD) at 405 nm in a Microplate Reader (Bio-Rad
Laboratories, CA, USA). Results were reported as titres
which are the reciprocal of the highest dilution that gave
a positive OD reading. A positive titre was defined as an
OD reading that was at least two times greater than the
values for a negative sample.
PBMC Isolation and Bioplex Cytokine Assays
PBMCs were isolated following the protocol described
by Buchanan et al [58]. Stimulation of PBMCs were
performed in 96-well, round-bottom plates (Nunc,
Naperville, Ill., USA) using AIM-V® medium supplemented
with 10% fetal bovine serum (Invitrogen, Burlington, ON),
2 mM L -glutamine, 50 μM 2-mercaptoethanol and 10 μg/
mL polymyxin B sulfate (Sigma-Aldrich for all) as de-
scribed before [12]. For each treatment, 5x105 cells were
cultured for 72 h in triplicate wells with media alone or
20 μg/ml OVA in 200 μL total volume. Culture superna-
tants were harvested and stored at –20°C until assayed for
IL-10 and IFN-γ using Bioplex Cytokine Assay.
Bioplex bead coupling was performed as per the
manufacturer’s instructions. The reagents were as fol-
lows: Coating antibody: monoclonal anti-swine IL-10
(Invitrogen ASC0104), Detection antibody: monoclonal
anti-swine IL-10 biotin (Invitrogen ASC9109), Standard:
recombinant swine IL-10 (Invitrogen PSC0104) and
Coating antibody: monoclonal anti-swine IFN-γ (Fisher
Scientific Ltd, ENMP700), Detection antibody: monoclo-
nal anti-swine IFN-γ (Fisher Scientific Ltd,ENPP700;
biotinylated in-house), Standard: recombinant swine
IFN-γ (Ceiba Geigy). The multiplex assay was carried
out in a 96 well Grenier Bio-One Fluotrac 200 96 F
black (VWR CanLab Mississauga, ON, #82050-754)
which allows washing and retention of the Luminex
beads. The porcine IFN-γ and porcine IL-10 protein
standards were added to the wells at 50 μl per well at an
initial concentration of 2000 pg/mL and 5000 pg/ml,
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standard curve. The PBMC supernatants were predi-
luted 1:3 and added to the wells at 50 μL per well. The
two beadsets conjugated with the IFN-γ and IL-10 anti-
gens were vortexed for 30 s followed by sonication for
another 30 s to ensure total bead dispersal. The bead
density was adjusted to 1200 beads per μl in PBS-BN
(1x PBS + 1% BSA (Sigma-Aldrich) + 0.05% sodium
azide (Sigma-Aldrich), pH 7.4) and 1 μL of each bead-
set was added to 49 μl of the PBSA + 1% New Zealand
Pig Serum (Sigma-Aldrich P3484) + 0.05% sodium azide
(Sigma-Aldrich) which was then added to each well.
The plate was sealed with plate sealer (Fisher Scientific
Ltd, #12565491) and covered with foil lid. The plate
was agitated at 800 rpm for one hour at room
temperature. After one hour incubation with serum,
the plate was washed using the Bio-Plex ProII Wash
Station (Bio-Rad Laboratories; soak 20 s, wash with
150 μL PBST three times). A 50 μL cocktail consist-
ing of porcine IFN-γ (Fisher Scientific Ltd, (Endogen);
1/300 (which was biotinylated in-house) and biotinyl-
ated porcine IL-10 (Invitrogen; 0.5 μg/mL) was added
to each well. The plate was again sealed, covered and
agitated at 800 rpm for 30 minutes at room tem-
perature then washed again as indicated above. A 50 μL
volume of Streptavidin R-Phycoerythrin (RPE) (dilutedFigure 4 OVA-specific cytokine production by PBMCs from piglets gav
at four weeks of age. Piglets (n = 5/group) were gavaged and i.p. immuniz
PBMCs obtained four weeks post i.p. immunization. PBMCs were re-stimulat
collected and measured by BioPlex assay. Each data point represents an indto 5 μg/mL; Cedarlane, Burlington, ON; # PJRS20) was
added to each well. The plate was again sealed, covered
and agitated at 800 rpm for 30 minutes at room
temperature and washed as indicated above. A 100 μL
volume of 1 × Tris-EDTA was added to each well and
then the plate was vortexed for 5 minutes before read-
ing on the Luminex100 xMAP™ instrument (Luminex,
Toronto, ON) following the manufacturer’s instruc-
tions and as described in [59]. The instrument was set
up to read beadsets in regions 43 and 28 for IFN-γ and
IL-10, respectively. A minimum of 60 events per bead-
set were read and the median value obtained for each
reaction event per beadset. For all samples the multi-
plex assay mean fluorescent intensity (MFI) data was
corrected for subtracting the background levels.
Statistical analysis
The outcome data from this study were not normally
distributed and therefore, differences among experimen-
tal groups were tested using Kruskal-Wallis analysis and
medians were compared using Dunn’s test. In Figure 4,
significance was determined using Mann-Whitney test.
Differences were considered significant if p < 0.05. All
statistical analyses and graphing were formed using
GraphPad Prism 5 software (GraphPad Software, San
Diego, CA).aged with OVA subunit vaccine then i.p. immunized with OVA/IFA
ed as described in Figure 1. IL-10 production was measured from
ed with OVA or media ex vivo. After 72 hours, the supernatants were
ividual animal and median values are indicated by horizontal lines.
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